Related Experiment Video
Updated: May 9, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Transcriptomic analysis of insulin-sensitive tissues from anti-diabetic drug treated ZDF rats, a T2DM animal model
Yo Na Kim1, Sangok Kim, Il-Yong Kim
1Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Research Institute for Veterinary Science, BK21 Program for Veterinary Science, Seoul National University, Seoul, Korea.
Abstract:
Gene expression changes have been associated with type 2 diabetes mellitus (T2DM); however, the alterations are not fully understood. We investigated the effects of anti-diabetic drugs on gene expression in Zucker diabetic fatty (ZDF) rats using oligonucleotide microarray technology to identify gene expression changes occurring in T2DM. Global gene expression in the pancreas, adipose tissue, skeletal muscle, and liver was profiled from Zucker lean control (ZLC) and anti-diabetic drug treated ZDF rats compared with those in ZDF rats. We showed that anti-diabetic drugs regulate the expression of a large number of genes. We provided a more integrated view of the diabetic changes by examining the gene expression networks. The resulting sub-networks allowed us to identify several biological processes that were significantly enriched by the anti-diabetic drug treatment, including oxidative phosphorylation (OXPHOS), systemic lupus erythematous, and the chemokine signaling pathway. Among them, we found that white adipose tissue from ZDF rats showed decreased expression of a set of OXPHOS genes that were normalized by rosiglitazone treatment accompanied by rescued blood glucose levels. In conclusion, we suggest that alterations in OXPHOS gene expression in white adipose tissue may play a role in the pathogenesis and drug mediated recovery of T2DM through a comprehensive gene expression network study after multi-drug treatment of ZDF rats.
Insights
Anti-diabetic drugs alter gene expression in type 2 diabetes mellitus (T2DM). In white adipose tissue, drug treatment normalized oxidative phosphorylation (OXPHOS) gene expression, improving blood glucose levels in Zucker diabetic fatty rats.
Area of Science:
- Molecular Biology
- Genomics
- Endocrinology
Background:
- Gene expression alterations are linked to type 2 diabetes mellitus (T2DM), but the full scope remains unclear.
- Understanding these changes is crucial for developing effective T2DM therapies.
Purpose of the Study:
- To investigate the impact of anti-diabetic medications on gene expression profiles in T2DM.
- To identify specific gene expression networks and biological processes affected by T2DM and its treatment.
Main Methods:
- Oligonucleotide microarray technology was employed to profile global gene expression.
- Gene expression was analyzed in pancreatic, adipose, skeletal muscle, and liver tissues of Zucker lean control (ZLC) and Zucker diabetic fatty (ZDF) rats, with and without anti-diabetic drug treatment.
Main Results:
- Anti-diabetic drugs were found to regulate a substantial number of genes in ZDF rats.
- Analysis of gene expression networks revealed significant enrichment in pathways such as oxidative phosphorylation (OXPHOS), systemic lupus erythematosus, and chemokine signaling following drug treatment.
- Specifically, decreased OXPHOS gene expression in white adipose tissue of ZDF rats was normalized by rosiglitazone, correlating with improved blood glucose control.
Conclusions:
- Alterations in OXPHOS gene expression within white adipose tissue may contribute to T2DM pathogenesis.
- Drug-induced normalization of OXPHOS gene expression in adipose tissue appears to play a role in T2DM recovery.
- Comprehensive gene expression network analysis following multi-drug treatment provides insights into T2DM pathophysiology and therapeutic mechanisms.
